CE approved defibrillators offer a new approach to CRT treatment
Published date : 25 August 2012
Article date : 23 August 2012
Medtronic has won CE Mark approval for its Viva/Brava line of cardiac rhythm management devices. The medical device company said the Viva and Brava products, which are cardiac resynchronization therapy with defibrillation devices, feature a new algorithm it calls AdaptivCRT designed to optimize their CRT-D treatment.
The Viva/Brava family of devices offers clinicians and their patients a new approach to CRT treatment, providing therapeutic benefit and individualized care for patients
The AdaptivCRT software helped reduce right ventricular pacing by 44%, reducing unnecessary treatment and prolonging the life of the devices. The software also met its pre-specified safety and efficacy endpoints of non-inferiority as compared to the gold-standard comprehensive echocardiography-guided biventricular pacing, data. This is the basis for its pre-market approval application with the FDA.
